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ABSTRACT 
 
The 67 kDa laminin receptor (67LR) is a non-integrin cell-surface receptor for the 
extracellular matrix derived from the dimerization of a 37 kDa cytosolic precursor 
(37LRP). 67LR is highly expressed in human cancers and widely recognized as a 
molecular marker of metastatic aggressiveness. 
Phosphoprotein enriched in diabetes/phosphoprotein enriched in astrocytes 
(PED/PEA-15) is an anti-apoptotic protein whose expression is increased in several 
human cancers. In addition to apoptosis, PED/PEA-15 is involved in the regulation 
of other major cellular functions, including cell adhesion, migration, proliferation 
and glucose metabolism. 
A yeast two-hybrid screening identified 67LR as a PED/PEA-15 interacting 
partner. PED/PEA-15 molecular interaction with 67LR was confirmed by pull-
down experiments on lysates of PED/PEA-15 transfected HEK-293 cells. 
Overexpressed and endogenous PED/PEA-15 co-immunoprecipitated with 67LR in 
PED/PEA-15 transfected HEK-293 cells and in U-373 glioblastoma cells, 
respectively. 
PED/PEA-15 overexpression significantly increased 67LR-mediated HEK-293 cell 
adhesion and migration to laminin that, in turn, determined PED/PEA-15 
phosphorylation both in Ser-104 and Ser-116, through CamKII and PKC activation, 
thus enabling cell proliferation and resistance to apoptosis. 
Therefore, 67LR binding to laminin induces, through interaction with PED/PEA-
15, signals that may be crucial for tumor cell survival in a poor microenvironment. 
Indeed, high 67LR expression predicts for a more aggressive disease in several 
types of cancer.  
These considerations prompted us to search for small molecules that might target 
67LR activities. Since cancer cells overexpress 67LR, these compounds are 
expected to be cancer cell specific and minimally toxic. We conducted a 
computational screening of a diversity library of small molecules using the recently 
solved 67LR crystal structure, focusing on residues showed to be important for 
laminin binding. This analysis identified a lead compound that was characterized 
for its effects. This lead compound, NSC47924, could be the basis for the 
development of a new class of anti-cancer drugs, specifically targeting tumor 
invasion and metastasis. 
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1. INTRODUCTION 
 
1.1 The 67 kDa laminin receptor (67LR): structure and function 
 
The 67 kDa laminin receptor 67LR was originally identified as a non-
integrin cell surface receptor for the extracellular matrix molecule laminin (Rao 
1983). Laminins, other glycoproteins, collagen IV, and proteoglycans constitute a 
tight network to form the basement membrane. Laminin-1, a 900-kDa 
glycoprotein, is the major component of basement membranes and contains many 
bioactive domains involved in binding both integrin and nonintegrin receptors 
(Mecham 1991). Interactions between 67LR and laminin play a major role in 
mediating changes in the cellular environment that affect cell adhesion (Graf 
1987), neurite outgrowth (Mecham 1991), tumor growth and metastasis 
(Taraboletti 1993). 
67LR has been observed to act also as a cell surface receptor for the pathogenic 
prion protein (Gauczynski 2001) and a variety of viruses, including Sindbis virus 
(Nelson 2008).  
67LR derives from homo- or hetero-dimerization of a 37 kDa cytosolic precursor, 
the 37LRP (Rao 1989). The exact composition of the 67kDa dimer and the process 
by which it is formed from 37LRP remains obscure as evidence supports both a 
homo and a heterodimer (Scheiman et al 2010). 67LR was shown to be acylated 
by three fatty acids- palmitate, stearate and oleate - (Landowski et al 1995) and 
fatty acid synthesis is required for 67LR formation (Butò et al 1998). 
Interestingly, both human 67LR and the p40 ribosomal protein are encoded by the 
same gene, 37LRP/p40 (Jackers 1996). Sequence conservation of 37LRP/p40 
genes across species has been demonstrated, with evolution of the C-terminal tail, 
where is located the laminin binding domain, convergent with vertebrates (Ardini 
1998). Thus, human 37LRP shows a dual function, as a component of the 
translational machinery and as a precursor a cell surface receptor, which suggests 
that 37LRP is a multifunctional protein. Intracellular 37LRP is found on the 40S 
ribosome and polysomes (Ford 1999; Auth 1992) and in the nucleus (Kinoshita 
1998). Silencing 37LRP expression in mammalian cells induces G1 cell cycle 
arrest, protein translation shutdown, and loss of association with the polysomes 
(Scheiman 2010).  
67LR is located at the cell surface where it binds laminin through different binding 
domains, including residues 161–180 (peptide G), residues 205–229 and TEDWS-
containing C-terminal repeats (Castronovo 1991; Kazmin 2000). Laminin 
conformation changes upon binding 67LR, thus interacting more efficiently with 
integrins
 
(Magnifico 1996), becoming more sensitive to the action of proteolytic 
enzymes (Ardini 2002) and releasing motility fragments (Berno 2005). 
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67LR is co-expressed and can physically interact with the a6 integrin chain (Ardini 
1997). 
The minimal sequence of laminin that binds to 67LR is YIGSR, a pentapeptide 
localized on the short arm of the laminin, just below the cross intersection (Massia 
1993). 
Main functional regions of 67LR are reported in Figure 1. 
 
 
 
 
 
 
Fig. 1 Main functional regions and binding sites of 67LR. 
67LR has three regions involved in laminin binding: the C-terminal TWEDS-like repeats, the 
stretch corresponding to amminoacids 205-229, and the so called peptide G (aa.161-180). The 
peptide G is also a direct binding site for prion protein (PrP), whereas region 205-229 is a heparin-
dependent PrP-binding region. 
 
 
1.2 67LR in tumor invasion and metastasis 
67LR expression is increased in neoplastic cells as compared to their 
normal counterparts and directly correlates with an enhanced invasive and 
metastatic potential (Montuori 1996), mediated by high-affinity interactions 
between 67LR and laminin (Wewer 1987). Thus, 67LR overexpression is 
considered a molecular marker of metastatic aggressiveness in cancers of many 
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tissues, including breast, lung, ovary, prostate and also in leukaemia and 
lymphoma (Menard 1998; Montuori 1999; Chen 2002).  
The role of 67LR in tumor progression is based on the adhesive properties of this 
receptor. Indeed, a key step in the metastatic process is the attachment of tumor 
cells to laminin, the major component of basement membranes. Interactions 
between tumor cells and basement membranes are mediated by specific membrane 
receptors, including 67LR, whose association with tumor aggressiveness has been 
convincingly demonstrated.  
During intra-vasation and extra-vasation, cancer cells need to come into contact 
with and to degrade host basement membranes, before passing through. Proteolytic 
degradation of basement membrane components such as proteoglycans, collagen 
type IV, laminin-1, and laminin-5 occurs through the action of specific proteases 
secreted by tumor and stromal cells.  This proteolytic cleavage removes physical 
barriers to cell migration and converts ECM components in substrates suitable for 
migration (Giannelli 1997).  The invasive behavior of metastatic tumor cells 
correlates with the expression of many enzymes with hydrolytic activity as 
cysteine proteinases, cathepsin B, aspartic proteinases, cathepsin D, and serine 
proteinases, elastase (Yan et al 1998; Tetu et al 1999).  
In addition to promoting tumor cell adhesion and migration, 67LR increases 
cancer cell invasion by up-regulating the expression and the activity of proteolytic 
enzymes able to degrade the extracellular matrix, such as membrane type 1 matrix 
metalloproteinase (MT1-MMP), stromelysin 3, cathepsin L, and the matrix 
metalloproteinase MMP-2 (Berno 2005).  
An important role of 67LR in tumor progression has recently been described: mice 
inoculated with lung carcinoma cells expressing low levels of 67LR for the 
introduction of a specific antisense mRNA showed a prolonged survival (Satoh 
1999). Therefore, new therapies aimed to inhibit 67LR were tested in mice 
(Koliakos 2002); moreover, vaccines anti-67LR  have been tested successfully in 
the treatment of human metastatic renal cell carcinoma (Holtl 2002). 
A recent study on HT1080 fibrosarcoma cells revealed that the use of strategies to 
inhibit the interaction of 67LR with its ligand may interfere with the invasive 
potential of these cells. Anti-67LR antibodies such as the single-chain antibody 
scFv iS18, its full-length version and the polysulfated glycans HM2602 and 
pentosan polysulfate (SP-54) significantly inhibited the invasion of HT1080 cells. 
HT1080 cells transfected with recombinant lentiviral plasmids expressing small 
interfering RNAs (siRNAs) directed against LRP mRNA revealed reduced levels 
of LRP, concomitant with a significantly reduced invasive behavior (Zuber 2008). 
A novel Sindbis/Lenti pseudotype vector carrying short-hairpin RNA (shRNA) 
designed against 67LR effectively reduced its expression and specifically targeted 
tumors in vivo. Treatment of tumor-bearing severe combined immunodeficient 
(SCID) mice with this pseudotype vector significantly inhibited tumor growth 
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(Scheiman 2010). Thus, 67LR can be used as a target in novel therapies for tumor 
reduction and elimination. 
 
1.3 67LR crystal structure 
 
Computational methods for drug design are based on the three dimensional 
structure of relevant cell targets. A high-resolution crystal structure of the majority 
of 37LRP, residues 1 through 220 (abbreviated LamR220) has been recently 
determined (PDB code 3BCH) (Jamieson 2008). LamR220 binds laminin with 
similar affinity as the full-length 67LR and inhibits Sindbis virus infection in vitro. 
Based on analysis of sequence conservation and of the crystal structures of human 
37LRP and Archaeoglobus fulgidus S2 ribosomal protein, a laminin binding site 
has also been mapped (Jamieson 2010). The crystal structure of LamR is reported 
in Figure 2.  
                
 
Fig. 2 Crystal structure of human LamR.  
(a) Ribbon diagram of LamR220 with α helices colored red and β strands colored yellow. (b) 
Superimposition of LamR220 (cyan) and A. fulgidus S2p (1VI6)  (yellow). Regions of divergence 
between the two structures are colored red in the 67LR structure (residues 111-118 and 188-196). 
(c) LamR220 dimer. One protomer is colored magenta and the other cyan. Residues in the dimer 
interface are labeled. 
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1.4 Phosphoprotein enriched in diabetes/phosphoprotein enriched in astrocytes-
15 kDa (PED/PEA-15): structure and function 
 
A yeast two-hybrid screening using phosphoprotein enriched in 
diabetes/phosphoprotein enriched in astrocytes-15 kDa (PED/PEA-15) as a bait 
identified 67LR as an interacting partner.  
PED/PEA-15 is a 15-kDa ubiquitously expressed protein involved in the 
regulation of fundamental cellular functions, including apoptosis, proliferation, 
and glucose metabolism (Fiory 2009). PED/PEA-15 consists of a N-terminal 
nuclear export sequence, a death effector domain (DED), an extracellular regulated 
kinase (ERK) binding site, and two phosphorylation sites (Ser-104 and Ser-116) at 
the C terminus.  
PED/PEA-15 lacks enzymatic function and serves mainly as a molecular adaptor. 
Since it contains a DED, PED/PEA-15 regulates apoptosis by competitively 
inhibiting the binding of DED-containing proteins to initiator caspases (Condorelli 
1999; Kitsberg 1999). 
Apart from its apoptosis-related effects, PEA-15 is a potent modulator of mitogen-
activated protein kinase (MAPK) signaling cascades (Formstecher 2001). 
Unphosphorylated PED/PEA-15 binds ERK1/2 and prevents its translocation into 
the nucleus, thereby reducing the ERK1/2-mediated transcriptional activity and 
inhibiting cell proliferation (Callaway 2007; Renganathan 2005). 
Moreover, PED/PEA-15 is an endogenous substrate for protein kinase C (PKC), 
calcium/calmodulin-dependent protein kinase II (CAM kinase II) and Akt. PKC 
phosphorylates PED/PEA-15 at Ser-104  (Kubes 1998) and CAM kinase II or Akt 
at Ser-116 (Trencia 2003; Formisano 2005). Phosphorylation of PED/PEA-15 at 
Serine-104 prevents ERK1/2-binding, thus allowing cell proliferation; 
phosphorylation at Serine-116 enhances the binding to Fas-associated protein with 
death domain (FADD) and caspase 8, resulting in inhibition of apoptosis (Kubes 
1998; Trencia 2003). 
A model for control of PED phosphorylation is depicted in Figure 3. 
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Fig. 3 Phosphorylation status of PEA-15 modulates its function in blocking ERK-mediated 
transcription or DISC-mediated apoptosis 
A model for control of PEA-15 function by phosphorylation is depicted. Unphosphorylated PEA-
15 binds ERK and  prevents accumulation of active ERK in the nucleus, thus blocking transcription 
and slowing proliferation. Upon phosphorylation at Ser-104, PEA-15 cannot bind ERK. Upon 
phosphorylation at Ser-116, PEA-15 binds FADD and is thus recruited to the DISC in response to 
death receptor ligation. In this way, PEA-15 can integrate ERK- and FADD-dependent signalling 
pathways. 
 
 
1.5 PED/PEA-15 in tumorigenesis and cancer progression 
 
Because of its functional role in ERK signaling and apoptosis, increased 
PED/PEA-15 levels may affect tumorigenesis and cancer progression as well as 
sensitivity to anticancer agents. Overexpression of PED/PEA-15 in a transgenic 
mouse model increases the susceptibility to chemically induced skin cancer 
(Formisano 2005). Increased PEA-15 levels inhibit apoptosis in non small-cell 
lung cancer (Zanca 2008), B-cell chronic lymphocytic leukemia (Garofalo 2007), 
and thyroid cancer (Todaro 2006). In astrocytic tumors, PED/PEA-15 suppresses 
apoptosis (Hao 2001) and prevents glucose-induced cell death via the ERK 
pathway (Eckert 2008), suggesting that PED/PEA-15 promotes tumor cell survival 
in a poor microenvironment. 
PED/PEA-15 also plays a role in the regulation of cell adhesion and migration; 
indeed, its binding to ERK1/2 regulates the affinity for fibronectin (FN) of integrin 
adhesion receptors (Chou 2003). In astrocytes, PEA-15 prevents cell migration 
through a PKC delta-dependent pathway (Renault-Mihara 2006). It has been 
recently reported that PED/PEA-15 interacts with Rac1 and its overexpression 
increases cell migration/invasion in human non-small cell lung cancer cells (Zanca 
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2010).  
 
1.6 Structure-based drug design by “virtual screening”  
 
High 67LR expression predicts for a more aggressive disease in several 
cancer types. Indeed, 67LR binding to the laminin of basement membranes is a 
prerequisite for tumor invasion and metastatis (Montuori 1996). These 
considerations prompted us to search for small molecules inhibiting 67LR by a 
computational methods.  
The identification of a proper lead compound for a given molecular target is a 
critical step in drug discovery. To this end, computational tools are becoming 
increasingly important. Among them, “virtual screening” uses high-performance 
computing to analyze chemical databases and prioritize compounds for synthesis 
and assay. 
There are two fundamental approaches for virtual screening, a ligand-based 
approach or a receptor-based approach. The ligand-based approach aims to 
identify molecules with physical and chemical similarities to known ligands that 
are likely to interact with the target. Receptor-based virtual screening (RBVS) 
aims to exploit the molecular recognition between a ligand and a target protein to 
select out chemical entities that bind strongly to the active sites of biologically 
relevant targets for which the three-dimensional structures are known or inferred.  
RBVS starts with a 3-D structure of a target protein and a 3-D database of ligands 
and uses virtual filtering, followed by docking and scoring, to identify potential 
lead candidates. Docking and scoring algorithms generate subsets of a compound 
collection with a higher affinity against a target by predicting their binding mode 
(by docking) and affinity (by scoring), and retrieving those with the highest scores. 
The output of a docking-based screen is a set of 3-D models of the predicted 
binding mode of each compound against the receptor, together with a ranking that 
is a measure of the quality of fit. It thus represents the most detailed and relevant 
model for identifying a receptor-focused subset of ligands (Pierri 2010). 
We conducted a receptor based virtual screening of a diversity library of small 
molecules, using the recently solved 67LR cristal structure.  
In Figure 4 is depicted a model of “virtual screening” utilization. 
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Fig.4 Virtual screening The structure-based virtual screening begins with the application of 
docking algorithms that pose small molecules in the active site of a selected target, determining 
whether a given conformation and orientation of a ligand fits it. Algorithms are complemented by 
scoring functions that are designed to predict the biological activity through the evaluation of 
interactions between compounds and potential targets. 
Database of 3D 
structures  -3D coordinates generation 
Docking software 
Glide, FlexX 
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ligands in the active site 
3D model of the  
selected target  
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     (LigPrep) 
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  Force field 
- Hydrogen Bond 
- Ionic Interaction 
- Hydrophobic Interaction 
- Entropy Terms 
A scoring function is used to 
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to binding affinity 
Hit list  Best scored 
compounds 
Compound selection / Biochemical assays 
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2. AIMS OF THE STUDY 
 
In this study, we aimed to confirm 67LR interaction with both 
overexpressed and endogenous PED/PEA-15 and to investigate the functional 
consequences of this interaction on cell ahesion, invasion/migration, proliferation 
and apoptosis.  
Highly expressed 67LR regulates cancer aggressiveness and progression; indeed, 
high 67LR expression predicts for more aggressive disease in several types of 
cancer. These considerations prompted us to search for small molecules that might 
target 67LR on cancer cells.  
Although siRNAs, single chain antibodies and Sinbis viral vectors able to disrupt 
67LR interactions have been already described (Zuber 2008), we believe that small 
molecules with the same activity would be preferable; indeed, they are expected to 
have limited toxicity and to be orally available. Therefore, the identification of 
lead compounds with 67LR inhibitory activity could be a new promising tool for 
drug development in cancer therapy.  
To this aim, we conducted a virtual screening of a diversity library of small 
molecules, using the recently solved 67LR crystal structure, with a focus on 
residues important for laminin binding. This screening identified many compounds 
that, in this study, were selected and characterized for their effects on cell 
adhesion, migration, invasion and proliferation in response to laminin. 
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3.
 
MATERIALS AND METHODS 
 
3.1 Materials 
Media, sera, and antibiotics for cell culture and the Lipofectamine reagent 
were purchased from Invitrogen Ltd. (Paisley, United Kingdom).  Mouse 
monoclonal anti-p-Akt and p-PKC antibodies and polyclonal anti-AKT antibody 
were from Cell Signaling Technology (Danvers, MA). Mouse monoclonal anti-p-
ERK and PKC antibodies, rabbit policlonal anti-ERK2 and CamKII antibodies 
were from Santa Cruz Biotechnology (Santa Cruz, CA). Rabbit policlonal anti-p-
CamKII antibody was from Upstate (Billerica, MA). Rabbit anti-67LR antibody, 
also recognizing 37LRP, was from Abcam (Cambridge, UK). Anti-His-tagged 
recombinant 37LRP  antibody was made in our laboratory (Montuori 1999). Anti-
caspase-3 antibody was from Calbiochem (San Diego, CA). Anti-PED/PEA-15 
antibodies have been previously reported (Condorelli 1998). Antisera against 
phospho-Serine 104 and phospho-Serine 116 PED/PEA-15 were prepared in 
rabbits by PRIMM (Milan, Italy) and have been previously reported (Trencia 
2003). Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
reagents were purchased from Bio-Rad (Richmond, VA). Western blotting and 
ECL reagents were from Amersham (Arlington Heights, IL). All other reagents 
were from Sigma (St. Louis, MO).  
 
3.2 Transformation of Yeast Strains and β-Galactosidase Assay 
Plasmid DNA transformations were performed using an high efficiency 
lithium acetate procedure (Gietz 1992).  Cotransformants were propagated on Trp
-
, 
Leu
–
 plates, and potential interacting clones selected in Trp
–
, Leu
–
, His
–
, Ade
–
 
media. After 4 days of incubation at 30 °C, positive clones were further tested for 
β-galactosidase activity by liquid culture assays using the substrate o-nitrophenyl-
β-d-galactopyranoside as described by Miller et al. (Miller 1972). Clones of 
interest were analyzed by DNA sequencing and BLAST analysis. 
 
3.3 Cell culture 
The HEK-293 cell line was grown in DMEM medium supplemented with 
10% heat-inactivated FCS. Transfected cells were grown in DMEM additioned 
with 10% FBS and with the below indicated antibiotics. 
 
3.4 Transfection 
PED/PEA-15 cDNA and 37LRP cDNAs were cloned in a pcDNA3 vector 
with resistance to Geneticin, and the resulting plasmids were named PED/PEA-15-
pcDNA3 and 37LRP/pcDNA3. 5x10
6
 cells, cultured overnight in 100 mm tissue 
culture dishes, were transfected with 10 µg of PED/PEA-15-pcDNA3, 
37LRP/pcDNA3 or with the empty vector pcDNA3 by 60 µl of Lipofectamine for 
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5 h at 37°C (5% CO2). Transfected cells, named PED-293, 67LR-293 and V-293, 
were selected by Geneticin at 1.5 mg/ml for 15 days, pooled and cultured in the 
presence of 0.5 mg/ml Geneticin.  
 
3.5 Flow cytometric analysis of surface molecules 
Flow cytometric analysis of cell surface molecules was performed as 
described previously (Montuori 1999). Briefly, cells were incubated for 2 h at 4°C 
with 20 g/ml anti-67LR or isotype control antibodies. This step was followed by 
a second incubation for 1 h at 4°C with an anti-rabbit fluorescein-conjugated 
antibody. Finally, cells were washed and analyzed with a FACSCalibur 
Cytofluorimeter using Cell Quest software (Becton & Dickinson, San Fernando, 
CA). A total of 10
4 
events for each sample were acquired in all cytofluorimetric 
analyses. 
 
3.6 Western blot 
PED-293, LR-293 and V-293 cells were lysed in lysis buffer (50 mM 
HEPES [pH 7.5], 150 mM NaCl, 4 mM EDTA, 10 mM Na4PO7, 2 mM Na3VO4, 
100 mM NaF, 10% glycerol, 1% Triton X-100, 1 mM phenylmethylsulfonyl 
fluoride, 100 mg of aprotinin/ml, 1 mM leupeptin) for 120 min at 4°C. Cell lysates 
were clarified at 5,000 x g for 15 min and the protein content was measured by a 
colorimetric assay. 50 µg of protein was electrophoresed on a 15% SDS-PAGE 
and transferred onto a PVDF membrane. The membrane was blocked with 5% 
non-fat dry milk, and probed with with the primary and secondary antibodies; 
immunoreactive bands were detected by ECL according to the manufacturer's 
instructions.   
For the detection of phosphorylated PED/PEA-15, ERK1/2, PKC, CAMKII and 
Akt, 5 x 10
5
 V-293 and PED-293 cells were plated onto 30 mm plates previously 
coated for 24 h with laminin (20 g/ml in PBS).  After the indicated times, cells 
were washed with PBS, lysed and subjected to Western blot, as above described.    
 
3.7 PED/PEA-15/67LR interaction 
To investigate the interaction of PED/PEA-15 with 67LR, a 37LRP-His-tag 
fusion protein was generated. To this end, wild-type 37LRP cDNA (Montuori 
1999) was cloned into the pTrcHis B expression vector (Invitrogen, San Diego 
CA) and expressed in TOP-10 bacteria (Invitrogen). His-tagged 37LRP (His-
37LRP), was bound to nickel-NTA agarose beads, according to the procedures 
specified by Invitrogen. His-37LRP coniugated beads were washed and 
resuspended in 50 mmol/L Tris (pH 7.5)-0.1% Triton X-100. Lysates from 
PED/PEA-15-transfected 293 cells (500 μg) were incubated in the presence of 50 
μl of agarose-bound His-37LRP (approximately 2 μg) for 2 h at 4°C. Beads were 
washed four times with 50 mmol/L Tris (pH 7.5)-0.1% Triton X-100 and then 
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resuspended in Laemmli buffer followed by boiling for 6 min and centrifugation at 
25,000 × g for 3 min. Supernatants were analyzed by SDS-PAGE and blotting 
with anti-PED-PEA-15 antibodies. 
 
3.8 Coimmunoprecipitation 
Cells were harvested and scraped into 1 ml of lysis buffer  containing 
protease and phosphatase inhibitors. Total cell lysates were precleared with 20 l 
protein A-Sepharose beads (~50% slurry; Amersham Biosciences UK) at RT for 
30 min. 5 μg of anti-67LR, anti PED/PEA-15 or non-immune antibodies were 
added to 500 μg of cleared lysate, and incubated for 2 h at 4°C. Then, 20 μl of 
protein A-Sepharose beads were added and the lysates were incubated 30 min at 
RT. Immunoprecipitates were washed six times in lysis buffer and solubilized in 
2× SDS-PAGE sample buffer. Western blotting with anti-67LR antibody was used 
to assay PED/PEA-15 co-immunoprecipitated 67LR in V-293 and PED-293 cells. 
Western blotting with anti-PED/PEA-15 antibody was used  to detect 67LR co-
immunoprecipitated PED/PEA-15 in U-373 cells. Separately, 25 μg of total cell 
lysate was immunoblotted for 67LR and PED/PEA-15 to verify comparable 
expression in all samples. 
 
3.9 Rac1 pull-down assay 
V-293 and PED-293 cells were starved for 24 h and then plated on 
laminin-coated wells (10 g/ml) or BSA-coated wells, as a negative control, for 
the indicated times. After a quick wash with ice-cold PBS, cells were lysed with 
GST-Fish buffer (50mM Tris–HCl ph 7.4, 2mM MgCl2, 1% NP-40, 10% glycerol, 
100mM NaCl, 1mg/ml leupeptin, 1mg/ml pepstatin, 1mg/ml aprotinin, 1mM 
PMSF, and 2mM DTT). After 10 min at 4°C under agitation, cells were scraped 
and lysates were cleared by centrifugation in a precooled rotor. Five hundred 
micrograms of total protein extract was mixed with 10 g of GST-PAK-CRIB 
domain coupled to glutathione-sepharose beads (Upstate Biotechnology, Danvers, 
MA) and incubated 30 min at 4°C under agitation. Beads were then rinsed three 
times rapidly with 1ml of ice-cold GST-Fish buffer. The amounts of total Rac and 
Rac-GTP were estimated by immunoblot against Rac1 (Upstate Biotechnology). 
 
3.10 Adhesion Assay 
96-well flat-bottom microtiter plates were coated with 10 g/ml laminin 
(LM), vitronectin (VN), fibronectin (FN) or 1% heat-denatured BSA-PBS, as a 
negative control, and incubated overnight at 4°C. The plates were then blocked 1 h 
at room temperature with 1% heat-denatured BSA-PBS. Cells were harvested by 2 
mM EDTA-PBS and resuspended in Ca
2+
/Mg
2+
-containing PBS. 10
5
 cells were 
plated in each coated well and incubated for 1 h at 37°C. Attached cells were fixed 
with 3% paraformaldehyde in PBS for 10 min and then incubated with 2% 
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methanol for 10 min. The cells were finally stained for 10 min with 0.5% crystal 
violet in 20% methanol. Stain was eluted by 0.1 M sodium citrate in 50% ethanol, 
pH 4.2, and the absorbance at 540 nm was measured by a spectrophotometer. 
 
3.11 Cell proliferation assay 
Cell proliferation was evaluated by a MTS (3-(4,5-dimethylthiazole-2yl)–
5-(3- carboxymethoxyphenyl)–2-(4-sulfophenyl)-2H-tetrazolium, inner salt) and 
PES (phenazine ethosulfate) assay (CellTiter 96 AQueous One Solution Reagent) 
provided by Promega (Madison, WI, USA). V-293, PED-293 and LR-293 cells 
were serum-starved overnight using DMEM 0.1% BSA, plated at 10
4
 cells per 
well onto 96-well microtitre plates coated with 10 g/ml laminin (Costar 3599, 
Corning, New York, USA), in the same medium, and incubated for 1, 24, 48, 72 
and 168 h at 37 °C, with 5% CO2. 20 l/well of CellTiter 96 AQueous One Solution 
Reagent was added and, after 4 h incubation at 37 °C, the absorbance was 
determined by an ELISA reader (Bio-Rad, Hercules, California, USA) at a 
wavelength of 490 nm.  
 
3.12 Cell apoptosis assay 
V-293 and PED-293 cells were serum-starved overnight using DMEM 
0.1% BSA. 10
6 
cells were harvested by 2mM EDTA-PBS and plated in 100mm 
dishes precoated with 10 g/ml LM. After 24, 48 and 72 h at 37° C, 5% CO2, cells 
were lysed and apoptosis was analyzed using the ApoAlert Caspase-3 Colorimetric 
Assay Kit ( Clontech, CA, USA) that measures the proteolytic cleavage of the 
chromophore p-nitroanilide (pNA) by caspase-3. Some experiments were 
performed in the presence or in the absence of the anti-67LR antibody (10 g/ml). 
 
3.13 Cell Migration Assay  
Cell migration assays were performed in Boyden chambers using 8 µm 
pore size PVPF polycarbonate filters coated with 5 µg/ml FN, as an adhesion 
substrate. V-293, PED-293 and LR-293 cells (2x10
5
) were plated in the upper 
chamber in serum-free medium. 50 µg/ml laminin or serum free medium was 
added in the lower chamber. The cells were allowed to migrate for 6 h at 37°C, 5% 
CO2. The cells on the lower surface of the filter were then fixed in ethanol, stained 
with hematoxylin, and counted at 200x magnification (10 random fields/filter). In 
a separate set of experiments, transfected cells were preincubated for 1 h at room 
temperature with 20 µg/ml of a polyclonal antibody directed to 67LR and with non 
immune antibodies, as a negative control, or with 20 M NSC47924 or DMSO, as 
a negative control. 
 
3.14 Invasion assay 
The upper chamber of the Boyden apparatus was filled with 100 l of BD 
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Matrigel
TM
 (BD Biosciences, San Jose, CA). BD Matrigel
TM
 was diluted to 
1mg/ml in serum free culture medium and put into the top of the filter. Then it was 
incubated for 4 h for gelling. V-293, PED-293 and LR-293 cells were counted, 
treated as indicated above and allowed to invade toward 10% FCS, or medium 
alone, as a negative control. Invaded cells were measured as % over control. In a 
separate set of experiments, transfected cells were preincubated for 1 h at room 
temperature with 20 µg/ml of anti-67LR polyclonal antibodies and non immune 
antibodies, as a negative control, or with 20 M NSC47924 and DMSO, as a 
negative control. 
 
3.15 Statistical analysis 
Differences between groups were evaluated by the Student’s t test using 
PRISM software (GraphPad, San Diego, CA). P<0.05 was considered statistically 
significant. 
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4. RESULTS 
 
4.1 Isolation and identification of 37 kDa laminin receptor precursor (37LRP) 
as a novel PED/PEA-15 interacting protein 
To search for proteins specifically interacting with PED/PEA-15, a yeast 
two-hybrid system was established using the full-length ped/pea-15 gene (pG-
BKT7-ped/pea-15) as bait to screen a human HeLa library (Clontech). Upon HIS3 
selection, 45 β-galactosidase positive cDNA clones were detected. Based upon 
sequence analysis and BLAST searching, several clones were shown to match the 
37LRP sequence (Rao 1989). 
 
4.2 67LR interacts with PED/PEA-15 in vitro as well as in mammalian cells 
To verify the interaction of 67LR with PED/PEA-15, pull-down assays were 
performed with His-tag-fused recombinant 37LRP on lysates of 293 cells stably 
transfected with PED/PEA-15 (PED-293 cells) (Fig.5A). Recombinant 37LRP 
bound PED/PEA-15 in PED-293 cell extracts (Fig. 5B). No pull-down was 
detectable using His-tag bound agarose, indicating that 37LRP specifically binds 
PED/PEA-15 in vitro.  
Dimerization of 37LRP (Rao 1989; Landowski 1995) generates the mature form of 
the receptor, the 67 kDa laminin receptor (67LR). 37LRP is localized mostly in the 
cytoplasm, acting as a precursor for 67LR, but also as a ribosomal protein and in 
the nucleus, where it interacts with histones (Montuori 1996). 67LR is localized in 
the plasma membrane, where it binds laminin (LM) with high affinity, thus 
playing a crucial role in tumor invasion and metastasis (Rao 1989; Landowski 
1995; Castronovo 1991; Kazmin 2000; Montuori 1996).  
We sought to define the receptor form interacting with PED/PEA-15 by 
coimmunoprecipitation experiments in PED-293 cells, stably transfected with 
PED/PEA-15 cDNA and endogenously expressing 37LRP and 67LR (Fig.5C). 
Precipitation of lysates from PED-293 cells with anti-PED/PEA-15 antibodies 
followed by blotting with antibodies able to recognize both 37LRP and 67LR 
revealed co-precipitation of 67LR, indicating that PED/PEA-15 interacts with the 
mature membrane-bound form of the receptor (Fig.5C). Moreover, 
coimmunoprecipitation experiments in U-373 glioblastoma cells, endogenously 
expressing both PED/PEA-15 and 67LR (not shown), with anti-67LR antibodies 
followed by blotting with anti-PED/PEA-15 antibodies revealed co-precipitation 
(Fig.5D).  
Therefore, endogenous and overexpressed PED/PEA-15 specifically interacts with 
the mature membrane bound 67LR.  
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Fig.5. PED/PEA-15 interacts with 67LR.   
A: HEK-293 cells were transfected with PED/PEA-15 cDNA (PED-293) or with the empty vector 
(V-293). Transfected cells were lysed and 50 g of proteins were analyzed by Western blot with 
PED/PEA-15-specific antibodies. PED-293 cells express PED-PEA-15.  
B: Lysates from PED-293 cells were incubated with agarose-bound recombinant His-tagged 37 
kDa laminin receptor precursor (His-tag 37LRP) or with agarose bound His-tag (His-tag), as a 
negative control. His-tag 37LRP coniugated beads were washed, resuspended in Laemmli buffer, 
boiled and supernatants were analyzed by SDS-PAGE and blotting with anti-PED/PEA-15 
antibodies. Separately 50 g of total PED-293 lysate was immunoblotted (input). Recombinant 
37LRP binds PED/PEA-15. 
C: PED-293 cell lysates were incubated with 5 g of a polyclonal anti-PED/PEA-15 antibody or 
with non-immune immunoglobulins (Igs). The lysates were then immunoprecipitated with protein 
A Sepharose beads, washed and solubilized in Laemmli sample buffer. Western blotting with a 
polyclonal antibody, able to recognize both the 37LRP and the mature 67LR (anti-37LRP/67LR), 
was used to detect co-immunoprecipitated 67LR. Separately, 50 g of total cell lysate was 
immunoblotted for 37LRP/67LR (input). In PED/PEA-15 overexpressing cells, PED/PEA-15 is 
exclusively associated to the mature membrane-bound form of 67LR. 
D: U-373 cell lysates were incubated with 5 g of a polyclonal anti-67LR antibody. The lysates 
were then immunoprecipitated with protein A Sepharose beads, washed and solubilized in Laemmli 
sample buffer. Western blotting with a polyclonal anti-PED/PEA-15 antibody was used  to detect  
co-immunoprecipitated PED/PEA-15. Separately, 50 g of total cell lysate was immunoblotted for 
PED/PEA-15 (input). In U-373 glioblastoma cells, endogenously expressed PED/PEA-15 is 
associated to 67LR 
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4.3 PED/PEA-15 overexpression increases 67LR-mediated cell adhesion to 
laminin 
PED/PEA-15 is overexpressed in different human tumors, including breast 
and lung cancer, in which it determines refractoriness to anticancer therapy and 
resistance to apoptosis (Eckert 2008; Chou 2003; Renault-Mihara 2006; Zanca 
2010). Therefore, we investigated the functional effects of PED/PEA-15 
interaction with 67LR in PED/PEA-15 overexpressing cells.  
First, we sougt to investigate whether PED/PEA-15 overexpression could 
influence 67LR-mediated cell functions, namely, cell adhesion and migration to 
LM. Thus, V-293 and PED-293 cell adhesion to LM, fibronectin (FN) and 
vitronectin (VN) were evaluated. PED-293 cell adhesion to LM was significantly 
increased, as compared to V-293; conversely, PED-293 cell adhesion to VN and 
FN was not affected (Fig.6A). Moreover, the increase in PED-293 cell adhesion to 
LM was completely abrogated by cell pre-treatment with anti-67LR antibodies 
(Fig. 6B).  
Increased PED-293 cell adhesion to LM was not due to 67LR overexpression; 
indeed, V-293 and 293-PED cells showed comparable levels of 67LR expression 
by cytofluorimetric analysis (Fig. 6C). 
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Figure 6: PED/PEA-15 overexpression increases 67LR-mediated cell adhesion to laminin. 
A: V-293 (  ) and PED-293 (  ) cells were incubated for 1 hour on laminin (LM), vitronectin (VN), 
fibronectin (FN) or 1% heat-denatured BSA coated wells. The attached cells were fixed, 
permeabilized and stained with crystal violet. The stain was eluted and the absorbance at 540 nm 
(OD) was measured by a spectrophotometer. Cell adherence to BSA was subtracted from the 
reported values, representing the mean+S.D. of six experiments performed in triplicate. (*) p<0.05, 
as determined by the Student’s t test. PED-293 cell adhesion to LM was significantly increased, as 
compared to V-293; PED-293 cell adhesion to VN and FN was not affected. 
B: V-293 (  ) and PED-293 (  ) cells were plated on LM-coated wells in the presence of  20 g/ml  
of  nonimmune  immunoglobulins  (-)  or  anti-67LR  polyclonal  antibodies  (  ).  The attached 
cells were fixed and stained with crystal violet. The stain was eluted, and the absorbance at 540 nm 
was measured by a spectrophotometer. The values represent the means+S.D. of three experiments 
performed in triplicate. (*) p<0.05, as determined by the Student’s t test. Increased PED-293 cell 
adhesion to LM was abrogated by anti-67LR antibodies.  
C: Flow cytometric analysis of cell surface 67LR expression was evaluated by incubating V-293 
and PED-293 cells with a polyclonal anti-67LR antibody or an isotype control. Fluorescence 
intensity values are reported. Increased PED-293 cell adhesion to LM was not due to increased 
67LR expression; V-293 and 293-PED cells showed comparable levels of 67LR expression. 
 
 
4.4 PED and 67LR interaction increses cell migration/invasion toward 
laminin and affects ECM signaling 
PED/PEA-15 overexpression also resulted in increased cell migration to 
LM and matrigel invasion. Moreover, PED-293 cell pretreatment with an anti-
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67LR antibody was able to inhibit both cell migration to LM and matrigel invasion 
(Fig 7A, B).  
Therefore, PED/PEA-15 overexpression increases cell adhesion and migration to 
LM, through its physical interaction with 67LR. In order to study the downstream 
effects of PED/PEA-15 and 67LR interaction, we investigated ERK 1/2 pathway. 
Indeed, one of the most important effects of the activation of ERK1/2 pathway is 
the regulation of cell migration and invasion (Reddy 2003). PED/PEA-15 activates 
ERK/MAP Kinase through a Ras-dependent pathway (Ramos 2000). Moreover, 
Rac1, a member of mammalian Rho GTPase protein family, has been recently 
identified as PED/PEA-15-interacting protein (Zanca 2010). In a non small cell 
lung (NSCL) cancer cell line, PED/PEA-15 overexpression promotes Rac1 
activation in response to growth factor stimulation; in turn, active Rac1 increases 
ERK 1/2 phosphorylation (Zanca 2010; Eblen 2002). 
To determine the effect of PED/PEA-15 and 67LR interaction on ERK 1/2 and 
Rac1 activation after cell adhesion to LM, we plated control V-293 and PED-293 
cells on LM and then evaluated ERK 1/2 phosphorylation by Western blot analysis 
and Rac1 activation by pull-down assay.  
PED/PEA-15 overexpression was able to activate ERK 1/2, as compared to control 
V-293 cells (Fig.7C). Interestingly, cell adhesion to LM also promoted Rac1 
activation in PED/PEA-15 overexpressing cells, as compared to vector transfected 
cells (Fig. 7D).  
These results show for the first time that PED/PEA-15 overexpression promotes 
cell migration and invasion through LM, the major component of basal 
membranes. This effect is mediated by PED/PEA-15 interaction with 67LR, 
leading to increased cell adhesion to LM, Rac1 activation and ERK1/2 
phosphorylation. 
 
 24 
 
 
 
Figure 7: PED/PEA-15 overexpression increases 67LR-mediated migration to LM and matrigel 
invasion by activating ERK 1/2 and Rac1. 
A: V-293 (  ) and PED-293 (  ) cells were pre-incubated with nonimmune Ig or a polyclonal anti-
67LR antibody (  ), plated in Boyden chambers and allowed to migrate toward 50 g/ml LM on 
filters coated with 10 g/ml FN. The values are the mean+SD of three experiments performed in 
triplicate. (*) p<0.05, as determined by the Student’s t test. 
B: V-293  (  ) and PED-293 (  ) cells were pre-incubated with nonimmune Igs (-) or a polyclonal  
anti-67LR  antibody  (  ),  plated  in  Boyden  chambers  and  allowed  to  invade matrigel
TM
. The 
values are the mean+SD of three experiments performed in triplicate. (*) p<0.05, as determined by 
the Student’s t test. PED overexpression increased cell migration to LM and matrigel invasion; 
pretreatment with anti-67LR antibody inhibited both cell migration and invasion.  
C: V-293 and PED-293 cells were serum-starved and plated on uncoated or LM coated wells. The 
cells were harvested at the indicated times and lysed for Western blot analysis with anti-phospho-
ERKs and anti-ERK 2 (as a loading control) antibodies.  
D: V-293 and PED-293 cells were serum starved and then plated on uncoated or LM-coated wells 
for the indicated times. Rac1-GTP pull down assay was performed as described in Materials and 
Methods Section. The amounts of total Rac1 and Rac1-GTP were estimated by immunoblotting 
with Rac1. PED-293 cell adhesion to LM activated Rac1.  
PED/PEA-15 overexpression affected ECM signaling in 67LR expressing cells. 
 
 
4.5 Cell adhesion to LM allows cell proliferation in PED/PEA-15 
overexpressing cells by modulating PED/PEA-15 phosphorylation status 
We also investigated whether 67LR interaction with PED/PEA-15 could 
result in a modulation of PED/PEA-15 cellular functions. To this aim, we analyzed 
PED-293 and V-293 cell proliferation after adhesion to LM (Fig.8A). LM induced 
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a strong proliferative response in V-293 cells whereas PED/PEA-5 overexpression 
strongly inhibited cell proliferation, as reported (Zanca 2010; Glading 2007). 
However, after 24h, PED-293 cells recovered their proliferative capacity, albeit 
significantly slower than control cell, reaching them at 168h. V-293 and PED-293 
cell number, after adhesion to LM, followed the same pattern (Fig.8B).  
PED/PEA-15 can bind and retain into cytosol extracellular-regulated kinases 1/2 
(ERK 1/2), independently of their phosphorylation status, thus avoiding cell 
proliferation. On the other hand, PED/PEA-15 phosphorylation inhibits the 
interaction with ERK1/2 and abrogates the ability to block ERK1/2 transcriptional 
activities, thus enabling the proliferation of cells expressing high levels of 
PED/PEA-15 (Krueger 2005). 
Therefore, we asked whether 67LR-mediated cell adhesion to LM could alter 
PED/PEA-15 phosphorylation status, particularly after 24h, when PED-293 cells 
started to recover their proliferative capacity. To this aim, we analyzed PED/PEA-
15 phosphorylation status after PED-293 cell adhesion to LM or BSA, as a 
negative control (Fig.8C). After 1h of cell adhesion to LM, PED/PEA-15 became 
phosphorylated both in Ser-104 and in Ser-116; at 24h phosphorylation reached 
the maximum, and then remained unchanged up to 72h (not shown).  
Therefore, 67LR interaction with PED/PEA-15 increases cell adhesion and 
migration/invasion to LM and, in turn, stimulates PED/PEA-15 phoshorylation, 
thus enabling cell proliferation in response to LM. 
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Figure 8: 67LR interaction with PED/PEA-15 modulates LM-mediated cell proliferation and 
PED/PEA-15 phosphorylation status. 
A: V-293 (  ) and PED-293 (  ) cell proliferation were evaluated by a MTS assay after adhesion to 
LM-coated wells. At the indicated times 20 l/well of reagent was added and he absorbance (OD) 
was determined at a wavelength of 490 nm. The values are the mean+SD of three experiments 
performed in triplicate. (*) p<0.05, as determined by the Student’s t test. After 24 hours of 
adhesion to LM, PED-293 cells recovered their proliferative capacity,  reaching V-293 cells at 
168h.  
B: V-293 (  ) and PED-293 (  ) cell number was evaluated after adhesion to LM, at the indicated 
times. The values are the mean+SD of three experiments performed in triplicate. (*) p<0.05, as 
determined by the Student’s t test. 
C: PED-293 cells were serum-starved and plated on uncoated or LM coated wells. The cells were 
harvested at the indicated times and lysed for Western blot analysis with anti-phospho Ser-104
 
PED/PEA-15 and anti-phospho Ser-116 PED/PEA-15 antibodies; anti-actin antibodies were used 
as a loading control. 67LR-mediated cell adhesion to LM induced PED/PEA-15 phosphorylation 
both in Ser-104 and Ser-116. 
 
 
4.6 Cell adhesion to LM also inhibits apoptosis in PED/PEA-15 
overexpressing cells  
When phosphorylated in Ser-104 and Ser-116, PED/PEA-15 is recruited to 
the DISC and inhibits the apoptotic process (Renganathan 2005). Therefore, we 
asked whether LM-induced PED/PEA-15 phoshorylation could alter the apoptotic 
response to serum deprivation in PED-293 cells. To this aim, V-293 and PED-293 
cells were plated on LM in the absence of serum and apoptosis was evaluated at 
 27 
 
different times by ELISA assay. No apoptosis could be detected after 24h of serum 
deprivation; at 48h, V-293 cells underwent apoptosis whereas PED-293 cells 
showed a significant resistance (Fig. 9A). Noteworthy, cell-treatment with anti-
67LR antibodies restored PED-293 cell sensitivity to serum-deprivation induced 
apoptosis. After 48h of PED-293 cell adhesion to LM, resistance to apoptosis was 
also evidenced by the strong reduction of caspase 3 activation in respect to V-293 
cells (Fig. 9B).  
Therefore, 67LR-dependent binding to LM, through PED/PEA15 phosphorylation, 
can restore cell proliferation and inhibit the apoptotic process. 
 
4.7 Cell adhesion to laminin regulates PED-PEA-15 phosphorylation by 
activating protein Kinase C and calcium/calmodulin-dependent protein 
Kinase II 
We demonstrated that increased 67LR-mediated cell adhesion to LM in 
PED-PEA-15 overexpressing cells promotes cell proliferation and resistance to 
apoptosis by determining PED-PEA-15 phosphorylation both in Ser-104 and 
Serine-116.  
PED/PEA-15 is an endogenous substrate for protein kinase C (PKC), 
calcium/calmodulin-dependent protein kinase II (CAM kinase II), and Akt. In 
particular, PKC phosphorylates PED/PEA-15 at Ser-104 and CAM kinase II or 
Akt at Ser-116. Phosphorylation of PEA-15 at Serine-104 prevents ERK1/2-
binding and phosphorylation at Serine-116 enhances the binding to Fas-associated 
protein with death domain (FADD) and caspase 8, resulting in cell proliferation 
and inhibition of apoptosis (Renganathan 2005; Kubes 1998; Trencia 2003). 
Therefore, we investigated whether increased cell adhesion to LM could increase 
PKC, CAMKII or Akt activation in PED-293 cells as compared to vector 
transfected V-293 cells. After plating PED-293 cells on LM coated wells, 
PED/PEA-15, PKC, CAMKII and Akt phosphorylation status was evaluated by 
Western blot analysis with phosphospecific antibodies (Fig.9C). Akt was not 
activated whereas CAMKII was phosphorylated after 1 h, 24h, and up to 72h (not 
shown); thus, after cell adhesion to LM, Ser-116
 
could be phosphorylated by 
CAMKII. PKC was transiently activated at 1 h and could directly phosphorylate 
Ser-104.   
Therefore, increased 67LR mediated cell adhesion to LM in PED/PEA-15 
overexpressing cells stimulate a signal transduction pathway that, through PKC 
and CAMKII activation, determines PED/PEA-15 phosphorylation in both Ser-
104
 
and Ser-116.  PED/PEA-15 phosphorylation enables cell proliferation and 
resistance to apoptosis. 
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Figure 9: 67LR-mediated cell adhesion to LM inhibits apoptosis in PED/PEA-15 overexpressing 
cells and activates a signal transduction pathway responsible for PED/PEA-15  phosphorylation. 
 A: V-293 (  ) and PED-293 (  ) cells were plated on LM in the absence of serum and apoptosis was 
evaluated at different times by ELISA assay in the presence of  medium alone (-), 20 g/ml of 
nonimmune immunoglobulins (Igs) or anti-67LR polyclonal antibodies. The values are the 
mean+SD of three experiments performed in triplicate. (*) p<0.05, as determined by the Student’s t 
test. At 48h, PED-293 cells showed a significant resistance to apoptosis; anti-67LR antibodies 
restored PED-293 cell sensitivity to serum-deprivation induced apoptosis.  
B: V-293 and PED-293 cells were plated on LM for 48 h in the absence of serum and apoptosis 
was evaluated by Western blotting with anti-caspase 3 antibodies. A strong reduction of caspase 3 
activation was observed in PED-293 cells as compared to V-293 cells. 
C: V-293 and PED-293 cells were serum-starved and plated on LM coated wells. The cells were 
harvested at the indicated times and lysed for Western blot analysis with anti-phospho
Ser104 
PED/PEA-15, anti-phospho
Ser116
 PED/PEA-15, anti-phospho-CAMKII, anti-phospho-Akt and anti-
phospho-PKC antibodies; anti-PED/PEA-15, CAMKII, Akt and PKC antibodies were used as a 
loading control. 
 
 
4.8 Virtual screening of a diversity library of small molecules on 67LR 
The in silico screening of a library of chemical compounds for their 
potential to disrupt 67LR/LM interactions is the culmination of a long effort to 
find ways to inhibit 67LR-mediated cancer cell invasion and metastasis. It was 
made possible by the identification and characterization of a specific LM binding 
sequence on 67LR (Taraboletti 1993) and the recently published crystal structure 
of 67LR (Jamieson 2008).  
A diversity library of about 13,000 small molecules was screened using Autodock 
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(v 3.05) for possible binders to 67LR and to the specific site on 67LR that binds 
LM. The input describing the protein was prepared with the program Autodock 
Tools (ADT); it involved adding charges and non-bonded parameters to the 
protein structure file and orienting the protein to minimize the enclosing rectangle 
using an in-house program, Simulaid. The screening and the filtering of the docked 
poses were driven, respectively, by a script and a program (Dockres).  
Of the top-scoring molecules that docked on 67LR, 43 showed preferential 
docking on the sequence consisting of residues 161-180 and those were further 
tested in a cell-based assay. 
 
4.9 37LRP cDNA transfection in HEK-293 cells results in cell surface 
expression of the mature receptor and increased cell adhesion to laminin  
To obtain a cell system expressing high levels of 67LR, HEK-293 cells 
were transfected with a cDNA encoding the 37LRP fused at the C-terminal with a 
tag derived from a phage T7 sequence and a poly-histidine stretch (37LRP/His- 
tag), these cells were named LR-293. As a negative control, HEK-293 cells were 
transfected with the empty vector pcDNA3 and named V-293. 
37LRP/His-tag expression in transfected cells was demonstrated by Western blot 
analysis with both a specific anti-37LRP antibody, made in our laboratory against 
the His-tagged recombinant 37LRP, and an anti-T7 tag antibody (Fig. 10A). 
To verify that transfected 37LRP was correctly processed and expressed at the cell 
surface, flow cytometry analysis was performed on live V-293 and LR-293 cells 
with the anti-67LR antibody (Abcam). LR-293 cells showed increased 67LR 
surface expression in respect to V-293 cells (Fig. 10B). 
Moreover, the receptor expressed on LR-293 cell surface was functionally active; 
indeed, LR-293 cell adhesion to LM was significantly increased, as compared to 
V-293 cells, and such increase was completely abrogated by cell pre-treatment 
with anti-67LR antibodies (Fig. 10C).  
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Figure 10. 37LRP cDNA transfection in HEK-293 cells results in cell surface expression of the 
mature receptor and increased cell adhesion to laminin.  
A: HEK-293 cells were transfected with  a cDNA coding for 37LRP fused at the C-terminal with a 
tag derived from a phage T7 sequence and a poly-histidine stretch (37LRP/His-tag), and named 
LR-293, or with the empty vector, V-293. Transfected cells were lysed and 50 g of proteins were 
analyzed by Western blot with anti-His tagged recombinant 37LRP and T7 specific antibodies. 
B: Flow cytometric analysis of cell surface 67LR expression was evaluated by incubating V-293 
and LR-293 cells with a polyclonal anti-67LR antibody or an isotype control. Fluorescence 
intensity values are reported. 
C: B: V-293 (  ) and LR-293 (  ) cells were plated on LM-coated wells in the presence of  20 g/ml 
non immune  immunoglobulins or  anti-67LR  polyclonal  antibodies.  The attached cells were 
fixed and stained with crystal violet. The stain was eluted, and the absorbance at 540 nm was 
measured by a spectrophotometer. The values represent the means+S.D. of three experiments 
performed in triplicate. (*) p<0.05, as determined by the Student’s t test. 
 
 
4.10 LR-293 cell adhesion to laminin is inhibited by molecules selected by 
Virtual Screening 
In order to identify an inhibitor of 67LR interaction with LM, in vitro assays of 
LR-293 cell adhesion to LM were performed in the presence of the molecules 
selected by virtual screening.  
LR-293 cells were plated in LM-coated wells in the presence of the selected 
molecules, dissolved in DMSO and added at a concentration of 2x10
-5
 M, 
corresponding to 10,000-fold the affinity constant of 67LR for LM (2x10
-9
 M); 
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DMSO was used as negative control. Among the various molecules tested, only 
five were able to inhibit 67LR binding to LM (Fig. 11A). 
 
4.11 A molecule identified by a virtual screenig is a specific inhibitor of cell 
binding to laminin  
To verify their specificity, the five active compounds were tested by in 
vitro LR-293 cell adhesion to LM, fibronectin (FN) and vitronectin (VN). One 
compound selectively inhibited LR-293 cell adhesion to LM. This molecule, 1-((4-
methoxyphenylamino)methyl)naphthalene-2-ol, identified by the initials 
NSC47924, decreased cell binding to LM by 85% without affecting cell adherence 
to FN and VN (Fig.11B).  
      
Figure 11. Five top-scoring molecules from the virtual screening of a diversity library of small 
molecules inhibit LR-293 cell adhesion to laminin; but, only NSC47924 is specific. 
A: LR-293 cells were plated in LM-coated wells in the presence of the selected molecules, 
dissolved in DMSO and added at a concentration of 2x10
-5
 M, corresponding to 10,000-fold 67LR 
affinity constant for LM; DMSO was used as negative control (  ). Attached cells were fixed and 
stained with crystal violet. The stain was eluted, and the absorbance at 540 nm was measured. The 
values represent the means+S.D. of three experiments performed in triplicate. (*) p<0.05, as 
determined by the Student’s t test. Only five molecules inhibited LR-293 cell binding to LM. 
B: LR-293 cell adhesion to LM, fibronectin (FN) and vitronectin (VN), in the presence of 20 M 
NSC47924 (  ) or DMSO, as a negative control (  ). The attached cells were fixed and stained with 
crystal violet. The stain was eluted, and the absorbance at 540 nm was measured. The values 
represent the means+S.D. of three experiments performed in triplicate. (*) p<0.05, as determined 
by the Student’s t test. 1-((4-methoxyphenylamino)methyl)naphthalene-2-ol, identified by the 
initials NSC47924, specifically decreased 85% of LR-293 cell binding to LM.  
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4.12 NSC47924 is a specific inhibitor of 67LR-mediated cell binding to 
laminin and shows an Ic50 in the molar range 
In order to demonstrate the specificity of NSC47924 for 67LR-mediated 
binding to LM, cell adhesion experiments were performed on V-293 and LR-293 
cells. In the presence of NSC47924, the inhibition LM binding was 69% in 67LR-
293, compared with 39% observed in control V-293 cells (Fig.12A), that was 
exactly comparable to the inhibition obtained by anti-67LR antibodies (Fig. 10C). 
To assess the possibility of using NSC47924 in vivo, we calculated its IC50, i.e. the 
concentration of NSC47924 able to inhibit 50% of LR-293 cell binding to LM. 
LR-293 cell adhesion to LM was evaluated in the presence of increasing 
concentrations of the inhibitor and the IC50 was generated using nonlinear 
regression of binding curves in GraphPad Prism; it was found at 19.35 M  
(Fig.12B). 
 
 
 
Figure 12. NSC47924 is a specific inhibitor of 67LR-293 cell adhesion to laminin at a low Ic50. 
A: V-293  and  LR-293  cells were plated on LM-coated wells in the presence of 20 M NSC47924 
(  ), or DMSO (  ), as a negative control. The attached cells were fixed and stained with crystal 
violet. The stain was eluted, and the absorbance at 540 nm was measured by a spectrophotometer. 
The values represent the means+S.D. of three experiments performed in triplicate. (*) p<0.05, as 
determined by the Student’s t test. LM binding inhibition by NSC47924 was comparable to that 
previously obtained by anti-67LR antibodies. 
B: LR-293 cells were plated on LM-coated wells in the presence of increasing concentrations of 
NSC47924 and the IC50 was calculated by GraphPad Prism. 
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4.13 The specific 67LR inhibitor NSC47924 inhibitis cell proliferation, 
migration and invasion in response to laminin 
LM also induces proliferative and migratory signals; therefore, it was 
investigated whether NSC47924 was able to inhibit cell proliferation and 
migration/invasion in 67LR overexpressing cells. To this aim, proliferation assays 
were performed on LR-293 cells after adhesion to LM, in the presence or in the 
absence of 20 M NSC47924. The compound significantly inhibited LR-293 cell 
the proliferation, as compared to vehicle treated cells (Fig. 13A). In addition, 
NSC47924 significanly inhibited LR-293 cell migration to LM and matrigel 
invasion, as compared to vehicle treated cells (Fig. 13B,C). 
Figure 13. The specific 67LR inhibitor NSC47924 inhibitis cell proliferation, migration and invasion 
in response to laminin. 
A: LR-293 were plated on LM-coated wells in the presence of DMSO (  ), as a negative control, or 20 μM 
NSC47924 (  ). At the indicated times 20 l/well of reagent was added and the absorbance (OD) was 
determined at a wavelength of 490 nm. The values are the mean+SD of three experiments performed in 
triplicate. (*) p<0.05, as determined by the Student’s t test.  
B: V-293  cells  (  )  LR-293 cells  (  )   were   pre-incubated   with   DMSO  (-) or 20 μM NSC47924 (+), 
plated in Boyden chambers and allowed to migrate toward 50 g/ml LM on filters coated with 10 g/ml 
FN. The values are the mean+SD of three experiments performed in triplicate. (*) p<0.05, as determined 
by the Student’s t test. 
C: V-293  cells   (  )   and  LR-293  cells (  ) were  preincubated with DMSO (-) or 20 μM NSC47924 (+),  
plated  in  Boyden  chambers  and  allowed  to  invade matrigel
TM
. The values are the mean+SD of three 
experiments performed in triplicate. (*) p<0.05, as determined by the Student’s t test. NSC47924 
significanly inhibited LR-293 cell proliferation, migration and invasion in response to LM. 
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5.CONCLUSION 
 
By yeast two hybrid screening, the 67 kDa laminin receptor (67LR) was identified 
as a new candidate partner of the anti-apoptotic protein phosphoprotein enriched in 
diabetes/phosphoprotein enriched in astrocytes (PED/PEA-15). In this study, we 
confirmed the interaction between 67LR and PED/PEA-15, through pull down and 
immunoprecipitation experiments, using both exogenous and endogenous proteins.  
Then, we investigated the effects of PED/PEA-15 overexpression, occurring in 
different human tumors, such as breast and lung cancer, on 67LR-mediated cell 
functions, namely, cell adhesion and migration to LM and matrigel invasion. We 
also investigated the downstream effects of PED/PEA-15 and 67LR interaction on 
extracellular matrix-derived signal transuction pathways.  
We showed for the first time that PED overexpression increases cell adhesion and 
migration to LM, the major component of basal membranes, through its interaction 
with 67LR. This effect is mediated by increased 67LR binding to LM, ERK1/2 
phosphorylation and Rac1 activation. Therefore, a PED/PEA-15 dependent signal 
transduction pathway, usually activated in response to growth factor stimulation 
(Zanca 2010), is also activated after cell adhesion to basement membranes, a 
prerequisite for tumor invasion and metastasis.  
PED/PEA-15 is involved in promoting cell migration and invasion, through its 
interaction with 67LR. Interestingly, it has been recently reported that 67LR is 
overexpressed in astrocytoma and its downregulation reduces the migratory 
activity of human glioma cells (Chen 2009). Findings on PED/PEA-15 are more 
controversial; it has been described a PED/PEA-15 mediated inhibition of cell 
migration/invasion in astrocytoma (Renault-Mihara 2006) whereas an increase has 
beeen shown in NSCLC (Zanca 2010). Our data confirm the last report. 
67LR is also involved in the regulation of cell proliferation and survival. Indeed, 
reduction of 67LR expression in HeLa cells results in apoptosis (Kaneda 1998); 
apoptosis is also observed in Hep3B cells upon reduction of 67LR (Susantad 
2008). 67LR has been implicated in cell signalling pathways that are important for 
cell survival as well (Givant-Horwitz 2004), making it a suitable target for novel 
cancer gene therapy (Scheiman 2010). 
In that regard, we demonstrated that 67LR and PED/PEA-15 interfere with each 
other’s function once bound together. In fact, PED/PEA-15 interaction with 67LR 
increases cell adhesion, migration and invasion to LM. When 67LR is active, it 
promotes PKC and CAMKII  activation. Active PKC facilitates PED/PEA-15 
phosphorylation on Ser104 and the consequent release of ERKs to the nucleus, 
thus allowing cell proliferation that, in PED/PEA-15 overexpressing cells is 
slowed (Glading 2007; Zanca 2010).  Active CAMKII facilitates PED/PEA-15 
phosphorylation on Ser116, thus enhancing the binding to DED containing 
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proteins and caspase 8 (Renganathan 2005; Kubes 1998; Trencia 2003) and 
inhibiting of apoptosis.  
Therefore, a PED/PEA-15 dependent signal transduction pathway, leading to cell 
proliferation and resistance to apoptosis and usually activated in response to 
growth factor stimulation, is also activated after 67LR mediated cell adhesion to 
basement membranes, a prerequisite for tumor invasion and metastasis. 
These considerations prompted us to search for small molecules that might target 
67LR activities. We conducted a computational screening of a diversity library of 
small molecules using the recently solved 67LR crystal structure, focusing on 
residues showed to be important for laminin binding. This analysis identified a lead 
compound, NSC47924, that specifically inhibited cell adhesion, migration, invasion 
and proliferation in response to LM in 67LR overexpressing cells.  
Since cancer cells overexpress 67LR, we expect this compound to be cancer cell 
specific and minimally toxic. Therefore, we are now evaluating NSC47924 in vivo 
activity by in vivo tumorigenicity and metastasis assay.   
This lead compound could be the basis for the development of a new class of anti-
cancer drugs, specifically targeting cell invasion and metastasis.  
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